查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401922

2030 年肺癌筛检市场预测：按癌症类型、诊断类型、年龄层、最终用户和地区进行的全球分析

Lung Cancer Screening Market Forecasts to 2030 - Global Analysis By Cancer Type, By Diagnosis Type, By Age Group, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球肺癌筛检市场规模为 34 亿美元，预计在预测期内复合年增长率为 10.1%，到 2030 年将达到 68 亿美元。

肺癌筛检涉及透过低剂量电脑断层扫描 (LDCT) 扫描早期发现肺癌的诊断测试。供高风险族群使用，例如重度吸烟者。早期发现可以及时介入并改善治疗结果。

据美国临床肿瘤学会称，肺癌是女性第二大常见癌症，预计到 2020 年将影响超过 235,000 名美国成年人。

患者对预防性医疗保健的需求不断增长

随着人们对早期检测益处的认识不断提高，患者越来越多地寻求预防措施，包括定期筛检，以便在早期和可治疗阶段发现潜在的健康风险，例如肺癌。在教育和意识提升宣传活动的推动下，主动健康管理的典范转移与对预防性医疗保健的日益重视同时发生。随着个人健康成为优先事项并选择预防性医疗保健措施，对方便和全面的肺癌筛检服务的需求将会增加，从而推动筛检计画的扩展和纳入常规医疗保健。

误报风险

儘管筛检计画旨在及早发现潜在病例，但它们存在固有的误报风险，这可能导致不必要的焦虑、后续观察和侵入性干预。误报可能是由于良性疾病或非癌性异常被检测为潜在癌性而导致的，使患者的经历复杂化并可能导致情绪困扰。除了给个人带来情绪负担外，误报还可能导致额外的医疗费用以及用于后续检测和不必要治疗的资源占用。

政府措施和资金

政府机构的支持性政策和财政支持可以提高筛检计画的可近性和可负担性，并提高普及。随着各国政府认识到早期癌症检测的社会和经济效益，他们正在加强投资力度，以提高肺癌筛检的认识和实施。资金支持可以促进研究、技术进步和筛选基础设施的建立。公共卫生机构、医疗保健提供者和政策制定者之间的合作努力将有助于制定有效的筛检计划，并向更广泛的人群提供预防措施。

对辐射暴露的担忧

筛检，尤其是电脑断层扫描（CT）检查，在提供有价值的诊断资讯的同时，也引发了人们对辐射潜在健康风险的担忧。电离辐射与罹患癌症的风险增加有关，因此频繁体检带来的累积暴露是一个挑战。重要的是要考虑早期癌症检测的好处与辐射暴露的潜在危害之间的平衡。为了解决这些问题，人们正在努力尽量减少辐射剂量，包括使用低剂量 CT 扫描。然而，风险继续阻碍人们参与筛检计划，并阻碍肺癌筛检的广泛普及。

COVID-19 的影响：

COVID-19 的疫情对市场产生了重大影响。医疗保健服务的中断、资源的重新分配以及对病毒传播的担忧导致了常规检查的减少。筛检和诊断的延误可能会延迟肺癌的检测并影响治疗结果。此外，对 COVID-19 的关注转移了预防性医疗保健工作的注意力和资源。随着卫生系统适应大流行的挑战，需要製定策略来重新启动并优先考虑肺癌筛检工作，并确保持续提供及时有效的预防性卫生服务。

预计 X 光部门在预测期内将是最大的

在预测期内，X射线领域的市场规模预计将扩大，并提供具有成本效益且广泛使用的诊断工具。儘管不如电脑断层扫描 (CT) 扫描灵敏，但 X 光在初步筛检中发挥重要作用，可以帮助检测肺部异常。携带式胸部 X 光检查通常用于检测肺癌的早期迹象，特别是在高风险族群中。 X 射线的易于引入有助于其广泛普及，并促进常规筛检和早期疗育，从而提高肺癌筛检计划的整体有效性。

预计医院业在预测期内复合年增长率最高。

预计医院产业在预测期内将出现良好的成长。医院配备电脑断层扫描、X光等先进影像技术，有助于全面且准确地进行肺癌筛检。包括肺科医生和放射科医生在内的多学科团队确保采用整体方法进行诊断和后续护理。医院在管理筛检（从风险评估到结果解释）方面发挥关键作用，并作为协调后续护理和介入措施的关键点。医院作为集中的医疗机构，对肺癌筛检倡议的可及性和有效性做出了重大贡献。

占有率最大的地区：

由于其强大的医疗基础设施、不断提高的预防医学意识以及肺癌的高盛行率，预计北美地区将占据最大的市场占有率。既定的筛检计划和先进的医疗技术有助于早期发现。在政府的支持政策和医疗机构的积极努力下，筛检服务的可近性正在不断改善。该地区对早期诊断的重视，加上患者对预防措施不断增长的需求，使北美处于肺癌筛检倡议的前沿，推动创新并塑造全球肺癌筛检市场的发展轨迹。

复合年增长率最高的地区：

预计亚太地区在预测期内将出现快速成长。该地区不断增长的人口和日益增加的肺癌盛行率凸显了对筛检服务的需求。政府的措施和先进医疗技术的引进正在促进市场的成长。随着中国和印度等国家的医疗保健系统优先考虑早期检测，亚太地区肺癌筛检市场预计将反映出积极主动的方法，以解决该地区日益增长的肺癌负担。我们正在见证显着的开拓。

提供免费客製化：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肺癌筛检市场：依癌症类型分类

  • 非小细胞肺癌（NSCLC）
  • 小细胞肺癌
  • 其他的

第六章全球肺癌筛检市场：依诊断类型

  • 低剂量电脑断层扫描 (LDCT)
  • X射线
  • 其他的

第七章全球肺癌筛检市场：依年龄组

  • 少于 50
  • 50岁以上

第八章全球肺癌筛检市场：依最终用户分类

  • 医院
  • 诊断中心
  • 其他最终用户

第九章全球肺癌筛检市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司简介

  • FUJIFILM Holdings Corporation
  • GE Healthcare
  • Siemens Healthineers AG
  • Canon Medical Systems Corporation
  • Koninklijke Philips NV
  • Medtronic
  • Nuance Communications, Inc.
  • PenRad Technologies, Inc.
  • Volpara Solutions Limited.
Product Code: SMRC24442

According to Stratistics MRC, the Global Lung Cancer Screening Market is accounted for $3.4 billion in 2023 and is expected to reach $6.8 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Lung cancer screening involves diagnostic tests to detect lung cancer in its early stages, typically through low-dose computed tomography (LDCT) scans. It is used for individuals at high risk, such as heavy smokers. Early detection allows for timely intervention, improving treatment outcomes.

According to the American Society of Clinical Oncology (2020), lung cancer is the second most common cancer in women and men is estimated to affect over 235,000 adults in the U.S in the year 2020.

Market Dynamics:

Driver:

Rising patient demand for preventive healthcare

With a growing awareness of the benefits of early detection, patients are actively seeking preventive measures, including routine screenings, to detect potential health risks such as lung cancer at an early and more treatable stage. The paradigm shift towards proactive health management, fueled by education and awareness campaigns, aligns with the rising emphasis on preventive care. As individuals prioritize their well-being and opt for preventive healthcare measures, the demand for accessible and comprehensive lung cancer screening services rises, driving the expansion and integration of screening programs into routine healthcare practices.

Restraint:

Risk of false positives

While screening programs aim to detect potential cases early, the inherent risk of false positives can lead to unnecessary anxiety, follow-up procedures, and invasive interventions. False positives can result from benign conditions or non-cancerous anomalies being detected as potentially cancerous, complicating patient experiences and potentially causing psychological distress. Beyond the emotional toll on individuals, false positives can lead to additional healthcare costs and resource utilization for follow-up tests and unnecessary treatments.

Opportunity:

Government initiatives and funding

Supportive policies and financial backing from governmental bodies enhance the accessibility and affordability of screening programs, encouraging widespread adoption. As governments recognize the societal and economic benefits of early cancer detection, they are increasingly investing in initiatives that promote lung cancer screening awareness and implementation. Funding can facilitate research, technological advancements, and the establishment of screening infrastructure. Collaborative efforts between public health agencies, healthcare providers, and policymakers contribute to the development of effective screening programs, making preventive measures accessible to a broader population.

Threat:

Radiation exposure concerns

While screening, particularly through computed tomography (CT) scans, provides valuable diagnostic information, it raises apprehensions about potential radiation-induced health risks. The cumulative exposure from frequent screenings poses a challenge, as ionizing radiation is associated with an increased risk of cancer development. Balancing the benefits of early cancer detection with the potential harm from radiation exposure is a critical consideration. Efforts to minimize radiation doses, such as the use of low-dose CT scans, are underway to address these concerns. However, the perceived risk may still deter individuals from participating in screening programs, hindering the broader adoption of lung cancer screenings.

COVID-19 Impact:

The COVID-19 pandemic has impacted the market profoundly. Disruptions in healthcare services, reallocation of resources, and concerns about virus transmission have led to a decline in routine screenings. Delays in screening and diagnosis may result in the identification of lung cancer at later stages, affecting treatment outcomes. Additionally, the focus on COVID-19 response has redirected attention and resources away from preventive healthcare initiatives. As healthcare systems adapt to pandemic challenges, there is a need for strategies to resume and prioritize lung cancer screening efforts, ensuring the continued provision of timely and effective preventive healthcare services.

The x-ray segment is expected to be the largest during the forecast period

Over the projection period, it is predicted that the x-ray segment will experience a larger market size, providing a cost-effective and widely accessible diagnostic tool. While not as sensitive as computed tomography (CT) scans, X-rays play a crucial role in initial screenings, aiding in the detection of lung abnormalities. Portable chest X-rays are commonly used to identify early signs of lung cancer, particularly in high-risk populations. The ease of X-ray implementation contributes to its widespread adoption, facilitating routine screenings and early interventions, thus enhancing the overall effectiveness of lung cancer screening programs.

The hospitals segment is expected to have the highest CAGR during the forecast period

During the forecast period, it is expected that the hospitals segment will experience lucrative growth. Equipped with advanced imaging technologies such as CT scans and X-rays, hospitals facilitate comprehensive and accurate lung cancer screenings. Their multidisciplinary teams, including pulmonologists and radiologists, ensure a holistic approach to diagnosis and subsequent care. Hospitals play a crucial role in managing screenings, from risk assessment to result interpretation, and serve as key points for coordinating follow-up care and interventions. As centralized healthcare institutions, hospitals contribute significantly to the accessibility and effectiveness of lung cancer screening initiatives.

Region with largest share:

The North America region is expected to witness largest market share, driven by a robust healthcare infrastructure, increasing awareness of preventive healthcare, and a high prevalence of lung cancer. Well-established screening programs and advanced medical technologies contribute to early detection efforts. Supportive government policies and the proactive approach of healthcare organizations enhance accessibility to screening services. The region's emphasis on early diagnosis, coupled with a rising patient demand for preventive measures, positions North America at the forefront of lung cancer screening initiatives, fostering innovation and shaping the trajectory of the global lung cancer screening market.

Region with highest CAGR:

During the forecast period, a rapid growth rate is anticipated in the Asia-Pacific region. The region's expanding population, coupled with a growing prevalence of lung cancer, underscores the demand for screening services. Government initiatives, coupled with the adoption of advanced medical technologies, contribute to the market's growth. As healthcare systems in countries like China and India prioritize early detection, the lung cancer screening market in Asia Pacific is witnessing significant development, reflecting a proactive approach to address the increasing burden of lung cancer in the region.

Key players in the market:

Some of the key players in Lung Cancer Screening market include FUJIFILM Holdings Corporation, GE Healthcare, Siemens Healthineers AG, Canon Medical Systems Corporation, Koninklijke Philips N.V., Medtronic, Nuance Communications, Inc., PenRad Technologies, Inc. and Volpara Solutions Limited.

Key Developments:

In August 2022, PenRad, a company that develops software to increase efficiency for breast imaging and lung screening, was acquired by Intelerad, a major international provider of enterprise medical imaging solutions. The purchase broadens Intelerad's product lines for lung analytics and mammography, enabling radiologists, technicians, and other healthcare workers to work more efficiently and fulfill increased demand for cancer screening while enhancing patient care.

In April 2023, Centers for Medicare & Medicaid Services (CMS) released a national coverage determination (NCD) that broadens coverage for lung cancer screening with Low Dose Computed Tomography (LDCT), to enhance health outcomes for those who have lung cancer,. In the U.S., lung cancer is one of the most prevalent malignancies and main reason for cancer-related mortality in both men and women.

Cancer Types Covered:

  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer
  • Other Cancer Types

Diagnosis Types Covered:

  • Low-dose computed tomography (LDCT)
  • X-ray
  • Other Diagnosis Types

Age Groups Covered:

  • Below 50
  • 50 and older

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Lung Cancer Screening Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Non-small Cell Lung Cancer (NSCLC)
  • 5.3 Small Cell Lung Cancer
  • 5.4 Other Cancer Types

6 Global Lung Cancer Screening Market, By Diagnosis Type

  • 6.1 Introduction
  • 6.2 Low-dose computed tomography (LDCT)
  • 6.3 X-ray
  • 6.4 Other Diagnosis Types

7 Global Lung Cancer Screening Market, By Age Group

  • 7.1 Introduction
  • 7.2 Below 50
  • 7.3 50 and older

8 Global Lung Cancer Screening Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Diagnostic Centers
  • 8.4 Other End Users

9 Global Lung Cancer Screening Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 FUJIFILM Holdings Corporation
  • 11.2 GE Healthcare
  • 11.3 Siemens Healthineers AG
  • 11.4 Canon Medical Systems Corporation
  • 11.5 Koninklijke Philips N.V.
  • 11.6 Medtronic
  • 11.7 Nuance Communications, Inc.
  • 11.8 PenRad Technologies, Inc.
  • 11.9 Volpara Solutions Limited.

List of Tables

  • Table 1 Global Lung Cancer Screening Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 4 Global Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 5 Global Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 6 Global Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 7 Global Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 8 Global Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 9 Global Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 10 Global Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 11 Global Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 12 Global Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 13 Global Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 14 Global Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 15 Global Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 16 Global Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 17 North America Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 18 North America Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 19 North America Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 20 North America Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 21 North America Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 22 North America Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 23 North America Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 24 North America Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 25 North America Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 26 North America Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 27 North America Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 28 North America Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 29 North America Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 30 North America Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 31 North America Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 32 North America Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 33 Europe Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 34 Europe Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 35 Europe Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 36 Europe Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 37 Europe Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 38 Europe Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 39 Europe Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 40 Europe Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 41 Europe Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 42 Europe Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 43 Europe Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 44 Europe Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 45 Europe Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 46 Europe Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 47 Europe Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 48 Europe Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 49 Asia Pacific Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 50 Asia Pacific Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 51 Asia Pacific Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 52 Asia Pacific Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 53 Asia Pacific Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 54 Asia Pacific Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 55 Asia Pacific Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 56 Asia Pacific Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 57 Asia Pacific Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 58 Asia Pacific Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 59 Asia Pacific Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 60 Asia Pacific Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 61 Asia Pacific Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 62 Asia Pacific Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 63 Asia Pacific Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 64 Asia Pacific Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 65 South America Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 66 South America Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 67 South America Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 68 South America Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 69 South America Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 70 South America Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 71 South America Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 72 South America Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 73 South America Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 74 South America Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 75 South America Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 76 South America Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 77 South America Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 78 South America Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 79 South America Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 80 South America Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 81 Middle East & Africa Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 Middle East & Africa Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 83 Middle East & Africa Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
  • Table 84 Middle East & Africa Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
  • Table 85 Middle East & Africa Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 86 Middle East & Africa Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
  • Table 87 Middle East & Africa Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
  • Table 88 Middle East & Africa Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
  • Table 89 Middle East & Africa Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
  • Table 90 Middle East & Africa Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 91 Middle East & Africa Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
  • Table 92 Middle East & Africa Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
  • Table 93 Middle East & Africa Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 94 Middle East & Africa Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 95 Middle East & Africa Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 96 Middle East & Africa Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)